Patents by Inventor Micah J. Niphakis

Micah J. Niphakis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230312499
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
    Type: Application
    Filed: November 8, 2022
    Publication date: October 5, 2023
    Inventors: Justin S. CISAR, Cheryl A. GRICE, Todd K. JONES, Micah J. NIPHAKIS, Jae Won CHANG, Kenneth M. LUM, Benjamin F. CRAVATT
  • Patent number: 11530189
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: December 20, 2022
    Assignees: H. LUNDBECKA/S, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M. Lum, Benjamin F. Cravatt
  • Publication number: 20210188793
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
    Type: Application
    Filed: March 8, 2021
    Publication date: June 24, 2021
    Inventors: Justin S. CISAR, Cheryl A. GRICE, Todd K. JONES, Micah J. NIPHAKIS, Jae Won CHANG, Kenneth M. LUM, Benjamin F. CRAVATT
  • Patent number: 11021453
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for a method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 1, 2021
    Assignees: LUNDBECK LA JOLLA RESEARCH CENTER, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M. Lum, Benjamin F. Cravatt
  • Patent number: 10859585
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 8, 2020
    Assignee: The Scripps Research Institute
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta, Jonathan Hulce
  • Publication number: 20200270223
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
    Type: Application
    Filed: December 17, 2019
    Publication date: August 27, 2020
    Inventors: Justin S. CISAR, Cheryl A. GRICE, Todd K. JONES, Micah J. NIPHAKIS, Jae Won CHANG, Kenneth M. LUM, Benjamin F. CRAVATT
  • Publication number: 20190293666
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Application
    Filed: December 28, 2018
    Publication date: September 26, 2019
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta, Jonathan Hulce
  • Patent number: 10168342
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: January 1, 2019
    Assignee: The Scripps Research Institute
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta, Jonathan Hulce
  • Publication number: 20180208568
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 26, 2018
    Inventors: Justin S. CISAR, Cheryl A. GRICE, Todd K. JONES, Micah J. NIPHAKIS, Jae Won CHANG, Kenneth M. LUM, Benjamin F. CRAVATT
  • Patent number: 9981972
    Abstract: Provided herein are N-hydroxy bicyclic hydantoin carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of serine hydrolases. Furthermore, the subject compounds and compositions are useful for the treatment of one or more of cancer, pain, diabetes, obesity/metabolic syndrome, epilepsy, traumatic brain injury, and inflammation.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: May 29, 2018
    Assignees: ABIDE THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Benjamin F. Cravatt, Armand B. Cognetta, Jonathan J. Hulce, Micah J. Niphakis, Todd K. Jones, Cheryl A. Grice
  • Patent number: 9957242
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: May 1, 2018
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, ABIDE THERAPEUTICS, INC.
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M Lum, Benjamin F. Cravatt
  • Publication number: 20170183353
    Abstract: Provided herein are N-hydroxy bicyclic hydantoin carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of serine hydrolases. Furthermore, the subject compounds and compositions are useful for the treatment of one or more of cancer, pain, diabetes, obesity/metabolic syndrome, epilepsy, traumatic brain injury, and inflammation.
    Type: Application
    Filed: May 20, 2015
    Publication date: June 29, 2017
    Inventors: Benjamin F. CRAVATT, Armand B. COGNETTA, Jonathan J. HULCE, Micah J. NIPHAKIS, Todd K. JONES, Cheryl A. GRICE
  • Publication number: 20170073320
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
    Type: Application
    Filed: September 21, 2016
    Publication date: March 16, 2017
    Inventors: Justin S. CISAR, Cheryl A. GRICE, Todd K. JONES, Micah J. NIPHAKIS, Jae Won CHANG, Kenneth M. LUM, Benjamin F. CRAVATT
  • Patent number: 9567302
    Abstract: Provided herein are carbamate compounds which may be useful in the treatment of for example, pain, solid tumors and/or obesity.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 14, 2017
    Assignees: Abide Therapeutics, Inc., The Scripps Research Institute
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Dong-Hui Wang, Olivia Weber, Benjamin F. Cravatt, Micah J. Niphakis, Armand Cognetta, Jae Won Chang
  • Patent number: 9487495
    Abstract: This disclosure provides compounds having the structure: wherein L3, R7, Rd and p are defined herein, which are modulators of MAGL and/or ABHD6. Further provided is the use of these compounds as medicinal agents, processes for their preparation, and pharmaceutical compositions that include the disclosed compounds. The disclosure also provides a method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: November 8, 2016
    Assignees: THE SCRIPTS RESEARCH INSTITUTE, ABIDE THERAPEUTICS
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M. Lum, Benjamin F. Cravatt
  • Publication number: 20160282369
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Application
    Filed: March 25, 2016
    Publication date: September 29, 2016
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta
  • Patent number: 9133148
    Abstract: This disclosure provides piperazine carbamates and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed piperazine carbamates as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: September 15, 2015
    Assignees: The Scripps Research Institute, Abide Therapeutics, Inc.
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M. Lum, Benjamin F. Cravatt
  • Publication number: 20150148330
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 28, 2015
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M. Lum, Benjamin F. Cravatt
  • Publication number: 20150080364
    Abstract: Provided herein are carbamate compounds which may be useful in the treatment of for example, pain, solid tumors and/or obesity.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Applicants: Abide Therapeutics, Inc., The Scripps Research Insititute
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Dong-Hui Wang, Olivia Weber, Benjamin F. Cravatt, Micah J. Niphakis, Armand Cognetta, Jae Won Chang
  • Publication number: 20150018335
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
    Type: Application
    Filed: January 7, 2013
    Publication date: January 15, 2015
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M. Lum, Benjamin F. Cravatt